Skip to main content

Table 1 Baseline characteristics of study patients stratified by the primary outcome

From: Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study

 

Overall

(N = 3972)

Survivors

(N = 3747)

Non-survivors

(N = 225)

P-value

Age, years

59.0 ± 11.9

58.4 ± 11.8

68.4 ± 10.6

< 0.001

Male sex, n (%)

3132 (78.8)

2993 (79.9)

139 (61.8)

< 0.001

Diabetes mellitus, n (%)

1299 (32.7)

1207 (32.2)

92 (40.9)

0.007

Hypertension, n (%)

2429 (61.2)

2262 (60.4)

167 (74.2)

< 0.001

Peripheral artery diseases, n (%)

159 (4.0)

141 (3.8)

18 (8.0)

0.002

Previous CABG or PCI, n (%)

583 (14.7)

548 (14.6)

35 (15.6)

0.702

STEMI, n (%)

3467 (87.3)

3269 (87.2)

198 (88.0)

0.741

Tumor diseases, n (%)

81 (2.0)

71 (1.9)

10 (4.4)

0.009

Liver diseases, n (%)

570 (14.8)

555 (14.8)

15 (6.7)

0.001

COPD, n (%)

32 (0.8)

27 (0.7)

5 (2.2)

0.014

Hemodynamics

    

Heart rate, bpm

77.4 ± 15.2

77.0 ± 14.9

83.4 ± 19.7

< 0.001

Systolic blood pressure, mmHg

124.7 ± 18.3

124.8 ± 18.1

123.0 ± 21.9

0.157

EF, %

53.8 ± 7.6

54.1 ± 7.4

48.6 ± 9.2

< 0.001

Cardiac arrest, n (%)

144 (3.6)

125 (3.3)

19 (8.4)

< 0.001

Laboratory tests

    

D-dimer, ng/mL

330 (220–590)

330 (220–550)

600 (320–1240)

< 0.001

LDL-C, mmol/L

2.7 ± 0.9

2.7 ± 0.9

2.7 ± 0.9

0.331

hsCRP, mg/L

7.16 (2.75–12.03)

7.00 (2.71–11.94)

11.17 (3.88–13.13)

< 0.001

Creatinine, µmoI/L

82.0 ± 25.1

81.0 ± 22.8

98.1 ± 47.1

< 0.001

Peak cTnI, ng/mL

2.50 (0.44–10.80)

2.48 (0.44–10.62)

2.97 (0.62–14.01)

0.093

GRACE score

109.7 ± 27.7

107.7 ± 25.9

142.0 ± 35.0

< 0.001

TIMI score

6.3 ± 1.8

6.2 ± 1.8

8.0 ± 2.0

< 0.001

Findings and details of PCI procedures

Culprit lesion, n (%)

    

Left main artery

95 (2.4)

80 (2.1)

15 (6.7)

< 0.001

Left anterior descending artery

1734 (43.7)

1632 (43.6)

102 (45.3)

 

Left circumflex

610 (15.4)

592 (15.8)

18 (8.0)

 

Right coronary artery

1515 (38.1)

1429 (38.1)

86 (38.2)

 

Bypass graft

18 (0.5)

14 (0.4)

4 (1.8)

 

Multi-vessel disease, n (%)

    

1-vessel disease

1002 (25.2)

966 (25.8)

36 (16.0)

< 0.001

2-vessel disease

1253 (31.6)

1201 (32.1)

52 (23.1)

 

3-vessel disease

1717 (43.2)

1580 (42.2)

137 (60.9)

 

Pre-PCI TIMI 0 flow, n (%)

2607 (65.6)

2441 (65.2)

166 (73.8)

0.008

Post-PCI TIMI 3 flow, n (%)

3822 (96.2)

3617 (96.5)

205 (91.1)

< 0.001

D2B time, mins

128 (95–202)

128 (95–201)

125 (90–219)

0.342

Stent placements, n (%)

3497 (88.0)

3321 (88.6)

176 (78.2)

< 0.001

Thrombus aspiration, n (%)

1649 (41.5)

1561 (41.7)

88 (39.1)

0.451

IABP, n (%)

381 (9.6)

323 (8.6)

58 (25.8)

< 0.001

Glycoprotein IIb/IIIa inhibitor, n (%)

534 (13.4)

507 (13.5)

27 (12.0)

0.513

Complete revascularization

before discharge, n (%)

1731 (43.6)

1669 (44.5)

62 (27.6)

< 0.001

Medications a

    

Aspirin, n (%)

3930 (98.9)

3718 (99.2)

212 (94.2)

< 0.001

P2Y12 inhibitors, n (%)

3936 (99.1)

3719 (99.3)

217 (96.4)

< 0.001

Statins, n (%)

3708 (93.4)

3507 (93.6)

201 (89.3)

0.013

  1. a Medication typically referred to drugs prescribed at discharge, or otherwise, drugs being used during hospitalization if patients failed to survive the hospitalization. bpm = beats per minutes, CABG = Coronary artery bypass grafting, COPD = chronic obstructive pulmonary diseases, cTnI = cardiac troponin I, D2B time = door-to-balloon time, EF = ejection fraction, GRACE score = the Global Registry of Acute Coronary Events risk score, hsCRP = high sensitivity C-reactive protein, IABP = intra-aortic balloon pump, LDL-C = low-density lipoprotein cholesterol, PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction, TIMI flow = the Thrombolysis In Myocardial Infarction grade flow, TIMI score = the Thrombolysis In Myocardial Infarction risk score